Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispec

Abstract

Antitumor immune responses are mediated primarily by T cells1. Downregulation of the major histocompatiblity complex (MHC) and the molecules that costimulate the immune response is associated with defective signaling by tumor cells for T-cell activation2–14. In vitro treatment with a combination of cytokines significantly increased the expression of MHC class I and adhesion molecules on tumor cell surfaces. When tumor cells were first incubated with a bispecific monoclonal antibody that binds antigen on tumor cells to CD28 on T cells, the modified tumor cells become immunogenic and are able to stimulate naive T cells, generating tumor-specific cytotoxic T cells in vitro. Immunization with the modified tumor cells elicits an immune response mediated by CD8+ T cells. This response protected against a challenge with parental tumor cells and cured established tumors. The approach was effective in both low immunogenic and nonimmunogenic tumor model systems. Modification of tumor cells with this two-step procedure may provide a strategy for development of tumor vaccines that is effective for cancer immunotherapy.

Cite this article

Guo, YJ., Che, XY., Shen, F. et al. Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies. Nat Med 3, 451–455 (1997). https://doi.org/10.1038/nm0497-451

View full text

>> Full Text:   Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispec